Skip to main content
Premium Trial:

Request an Annual Quote

Foundation, Array BioPharma Partner to ID Suitable Patients for Cancer Drugs

NEW YORK (GenomeWeb News) – Foundation Medicine announced today it is collaborating with Array BioPharma to assess patients who may be best suited for treatment with oncology treatments being developed by Array.

Foundation will use its genomic sequencing and analytical capabilities to evaluate potentially relevant molecular interactions that may shed light on patient response to Array's treatments. Array has a portfolio of targeted cancer treatments in the early stages of clinical development, and through the partnership it hopes to determine the genetic profile of tumors of patients treated with certain of its treatments.

The companies did not disclose which cancers are targeted by the partnership. Financial and other terms of the deal also were not disclosed.

Based in Cambridge, Mass., Foundation recently received CLIA certification for its laboratory. Last month, it and researchers from the Dana Farber Cancer Institute said they demonstrated that the company's assay being developed for cancer diagnostics can identify clinically actionable mutations from tumor samples.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.